Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 2/2013

01-06-2013

Endocrinopathies in HIV, AIDS and HAART

Authors: Amrit Bhangoo, Ninad Desai

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 2/2013

Login to get access

Excerpt

The United Nations AIDS Report in 2012 states that there are 34 million people living in the world with HIV/AIDS at the end of 2011; of these 69 % live in sub-Saharan Africa [1]. The Caribbean islands, Eastern Europe and Central Asia are the next three most affected regions of the world. The rate of new infections HIV has decreased to 2.5 million per year. In 2011 the number of people dying from AIDS had fallen down to 1.7 million from 2.3 million in 2005. The number of children who got infected with HIV was approximately 330,000 which have significantly fallen in the last 10 years. New perinatal HIV cases have substantially decreased due to HIV education, screening for HIV in pregnancy, peripartum, intrapartum care for HIV infected mother, formula feeding, postpartum care of the infant and new HAART medications. HIV infection has progressed from an acute disease to a chronic illness with developments in anti-retroviral therapies (HAART) along with better prophylaxis and treatment of opportunistic infections are the main contributors to the above advances [2]. In centers such as ours in Brooklyn, a significant cohort of long term survivors of perinatal HIV as well as a concentration large numbers of adults with HIV/AIDS help highlight the evolving clinical picture of this chronic disease and the impact of long term exposure to antiretroviral medications. There is an increase in morbidity and mortality due to secondary issues such as endocrine dys-regulation, although hormonal misbalance is not commonly seen. HIV and AIDS do involve almost all of the hormonal systems and axis (Fig. 1 and Table 1).
Table 1
Endocrine and Metabolic manifestation of HIV and AIDS
 
Endocrine & Metabolic Manifestations
GH axis
Increased GH sensitivity
GH resistance
Glucose Metabolism
Insulin resistance, Insulitis
Hyperglycemia, Hypoglycemia
Gonadal function
Hypothalamic hypogonadism
Adrenal function
Adrenal insufficiency
Impaired adrenal reserve
Glucocorticoid excess
Thyroid function
Primary or Secondary Hypothyroidism
Graves disease
Sick euthyroid syndrome
Calcium metabolism
Hypocalcemia
Lipid metabolism
HIV lipodystrophy
Hypercholesterolemia
Hypocholesterolemia
Hypertriglyceridemia
Literature
1.
go back to reference UNAIDS Report on the global AIDS epidemic. UNAIDS/WHO 2012;1–103 UNAIDS Report on the global AIDS epidemic. UNAIDS/WHO 2012;1–103
2.
go back to reference Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.PubMedCrossRef Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.PubMedCrossRef
3.
go back to reference Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360–5.PubMedCrossRef Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360–5.PubMedCrossRef
4.
go back to reference Eledrisi MS, Verghese AC. Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci. 2001;321:137–44.PubMedCrossRef Eledrisi MS, Verghese AC. Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci. 2001;321:137–44.PubMedCrossRef
5.
go back to reference Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, Lajeunie E, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Mineral Res Off J Am Soc Bone Mineral Res. 2004;19:402–9.CrossRef Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, Lajeunie E, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Mineral Res Off J Am Soc Bone Mineral Res. 2004;19:402–9.CrossRef
6.
go back to reference Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89:1200–6.PubMedCrossRef Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89:1200–6.PubMedCrossRef
7.
go back to reference Landonio S, Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, et al. Osteopenia and osteoporosis in HIV + patients, untreated or receiving HAART. Biomed Pharmacother Biomed Pharmacother. 2004;58:505–8. Landonio S, Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, et al. Osteopenia and osteoporosis in HIV + patients, untreated or receiving HAART. Biomed Pharmacother Biomed Pharmacother. 2004;58:505–8.
8.
go back to reference Mayer KH, Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42:108–14.CrossRef Mayer KH, Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42:108–14.CrossRef
9.
go back to reference Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;36:482–90.CrossRef Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;36:482–90.CrossRef
10.
go back to reference Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, et al. Reduced bone mineral density in HIV-positive individuals. AIDS (London, England). 2001;15:1731–3.CrossRef Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, et al. Reduced bone mineral density in HIV-positive individuals. AIDS (London, England). 2001;15:1731–3.CrossRef
11.
go back to reference Stone B, Dockrell D, Bowman C, McCloskey E. HIV and bone disease. Arch Biochem Biophys. 2010;503:66–77.PubMedCrossRef Stone B, Dockrell D, Bowman C, McCloskey E. HIV and bone disease. Arch Biochem Biophys. 2010;503:66–77.PubMedCrossRef
12.
go back to reference Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (London, England). 2000;14:F63–7.CrossRef Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (London, England). 2000;14:F63–7.CrossRef
13.
go back to reference Zirilli L, Orlando G, Diazzi C, Squillace N, Carani C, Guaraldi G, et al. Hypopituitarism and HIV-infection: a new comorbidity in the HAART era? J Endocrinol Investig. 2008;31:33–8. Zirilli L, Orlando G, Diazzi C, Squillace N, Carani C, Guaraldi G, et al. Hypopituitarism and HIV-infection: a new comorbidity in the HAART era? J Endocrinol Investig. 2008;31:33–8.
14.
go back to reference Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293–301.PubMedCrossRef Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293–301.PubMedCrossRef
15.
go back to reference Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:451–5.PubMedCrossRef Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:451–5.PubMedCrossRef
16.
17.
go back to reference Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1999;84:1932–7.PubMedCrossRef Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1999;84:1932–7.PubMedCrossRef
18.
go back to reference Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab. 2000;85:35–41.PubMedCrossRef Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab. 2000;85:35–41.PubMedCrossRef
19.
go back to reference Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;32:130–9.CrossRef Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;32:130–9.CrossRef
20.
go back to reference Meininger G, Hadigan C, Laposata M, Brown J, Rabe J, Louca J, et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metab Clin Exp. 2002;51:260–6.PubMedCrossRef Meininger G, Hadigan C, Laposata M, Brown J, Rabe J, Louca J, et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metab Clin Exp. 2002;51:260–6.PubMedCrossRef
21.
go back to reference Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E296–303.PubMedCrossRef Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E296–303.PubMedCrossRef
22.
go back to reference Seybold U. Metabolic syndrome and cardiovascular diseases in HIV patients. MMW Fortschr Med. 2012;154 Suppl 1:30–1.PubMedCrossRef Seybold U. Metabolic syndrome and cardiovascular diseases in HIV patients. MMW Fortschr Med. 2012;154 Suppl 1:30–1.PubMedCrossRef
23.
go back to reference Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. 2007;30:113–9.PubMedCrossRef Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. 2007;30:113–9.PubMedCrossRef
24.
go back to reference Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39:44–54.PubMedCrossRef Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39:44–54.PubMedCrossRef
25.
go back to reference Coll B, Parra S, Alonso-Villaverde C, de Groot E, Aragones G, Montero M, et al. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine. 2006;34:51–5.PubMedCrossRef Coll B, Parra S, Alonso-Villaverde C, de Groot E, Aragones G, Montero M, et al. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine. 2006;34:51–5.PubMedCrossRef
Metadata
Title
Endocrinopathies in HIV, AIDS and HAART
Authors
Amrit Bhangoo
Ninad Desai
Publication date
01-06-2013
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 2/2013
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-013-9249-5

Other articles of this Issue 2/2013

Reviews in Endocrine and Metabolic Disorders 2/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.